Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms.
Advantages of Novel Drug Delivery System are: Optimum dose at the right time and right location, efficient use of expensive drugs, excipients and reduction in production cost, Beneficial to patients, better therapy, improved comfort and standard of living.
The global Novel Drug Delivery Systems market size was valued at US$ 25460 million in 2023 and is forecast to a readjusted size of USD 28540 million by 2030 with a CAGR of 1.7% during review period.
Global Novel Drug Delivery Systems key players include Amgen, Teva, Roche, UCB (Union Chimique Belge), etc. Global top four manufacturers hold a share over 40%.
North America is the largest market, with a share about 50%, followed by Asia-Pacific and Europe, both have a share over 40 percent.
In terms of product, PEGylated Proteins & Polypeptides is the largest segment, with a share about 40%. And in terms of application, the largest application is Hospitals & Clinic, followed by Cancer Treatment Centers, etc.
This report is a detailed and comprehensive analysis for global Novel Drug Delivery Systems market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Novel Drug Delivery Systems market size and forecasts, in consumption value ($ Million), 2019-2030
Global Novel Drug Delivery Systems market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Novel Drug Delivery Systems market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Novel Drug Delivery Systems market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Novel Drug Delivery Systems
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Novel Drug Delivery Systems market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Teva, Roche, UCB (Union Chimique Belge), Celgene, Merck, Gilead Sciences, Sanofi, Pfizer, Takeda, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Novel Drug Delivery Systems market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segmentation
Novel Drug Delivery Systems market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Liposomes
PEGylated Proteins & Polypeptides
Polymer Nanoparticle
Protein鈥揹rug Conjugates
Others
麻豆原创 segment by Application
Hospitals & Clinic
Cancer Treatment Centers
Others
麻豆原创 segment by players, this report covers
Amgen
Teva
Roche
UCB (Union Chimique Belge)
Celgene
Merck
Gilead Sciences
Sanofi
Pfizer
Takeda
Bausch&Lomb
Samyang Biopharmaceuticals
Johnson & Johnson
TOLMAR
Astellas
AMAG Pharmaceuticals
AbbVie
Dr Reddy
AstraZeneca
Aspen
Acrotech Biopharma
TWi Pharmaceuticals
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Novel Drug Delivery Systems product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Novel Drug Delivery Systems, with revenue, gross margin, and global market share of Novel Drug Delivery Systems from 2019 to 2024.
Chapter 3, the Novel Drug Delivery Systems competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Novel Drug Delivery Systems market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Novel Drug Delivery Systems.
Chapter 13, to describe Novel Drug Delivery Systems research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Novel Drug Delivery Systems by Type
1.3.1 Overview: Global Novel Drug Delivery Systems 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Novel Drug Delivery Systems Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Liposomes
1.3.4 PEGylated Proteins & Polypeptides
1.3.5 Polymer Nanoparticle
1.3.6 Protein鈥揹rug Conjugates
1.3.7 Others
1.4 Global Novel Drug Delivery Systems 麻豆原创 by Application
1.4.1 Overview: Global Novel Drug Delivery Systems 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospitals & Clinic
1.4.3 Cancer Treatment Centers
1.4.4 Others
1.5 Global Novel Drug Delivery Systems 麻豆原创 Size & Forecast
1.6 Global Novel Drug Delivery Systems 麻豆原创 Size and Forecast by Region
1.6.1 Global Novel Drug Delivery Systems 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Novel Drug Delivery Systems 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Novel Drug Delivery Systems 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Novel Drug Delivery Systems 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Novel Drug Delivery Systems 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Novel Drug Delivery Systems 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East & Africa Novel Drug Delivery Systems 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Amgen
2.1.1 Amgen Details
2.1.2 Amgen Major Business
2.1.3 Amgen Novel Drug Delivery Systems Product and Solutions
2.1.4 Amgen Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Amgen Recent Developments and Future Plans
2.2 Teva
2.2.1 Teva Details
2.2.2 Teva Major Business
2.2.3 Teva Novel Drug Delivery Systems Product and Solutions
2.2.4 Teva Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Teva Recent Developments and Future Plans
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business
2.3.3 Roche Novel Drug Delivery Systems Product and Solutions
2.3.4 Roche Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Roche Recent Developments and Future Plans
2.4 UCB (Union Chimique Belge)
2.4.1 UCB (Union Chimique Belge) Details
2.4.2 UCB (Union Chimique Belge) Major Business
2.4.3 UCB (Union Chimique Belge) Novel Drug Delivery Systems Product and Solutions
2.4.4 UCB (Union Chimique Belge) Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 UCB (Union Chimique Belge) Recent Developments and Future Plans
2.5 Celgene
2.5.1 Celgene Details
2.5.2 Celgene Major Business
2.5.3 Celgene Novel Drug Delivery Systems Product and Solutions
2.5.4 Celgene Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Celgene Recent Developments and Future Plans
2.6 Merck
2.6.1 Merck Details
2.6.2 Merck Major Business
2.6.3 Merck Novel Drug Delivery Systems Product and Solutions
2.6.4 Merck Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Merck Recent Developments and Future Plans
2.7 Gilead Sciences
2.7.1 Gilead Sciences Details
2.7.2 Gilead Sciences Major Business
2.7.3 Gilead Sciences Novel Drug Delivery Systems Product and Solutions
2.7.4 Gilead Sciences Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Gilead Sciences Recent Developments and Future Plans
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Novel Drug Delivery Systems Product and Solutions
2.8.4 Sanofi Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Sanofi Recent Developments and Future Plans
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer Novel Drug Delivery Systems Product and Solutions
2.9.4 Pfizer Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Pfizer Recent Developments and Future Plans
2.10 Takeda
2.10.1 Takeda Details
2.10.2 Takeda Major Business
2.10.3 Takeda Novel Drug Delivery Systems Product and Solutions
2.10.4 Takeda Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Takeda Recent Developments and Future Plans
2.11 Bausch&Lomb
2.11.1 Bausch&Lomb Details
2.11.2 Bausch&Lomb Major Business
2.11.3 Bausch&Lomb Novel Drug Delivery Systems Product and Solutions
2.11.4 Bausch&Lomb Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 Bausch&Lomb Recent Developments and Future Plans
2.12 Samyang Biopharmaceuticals
2.12.1 Samyang Biopharmaceuticals Details
2.12.2 Samyang Biopharmaceuticals Major Business
2.12.3 Samyang Biopharmaceuticals Novel Drug Delivery Systems Product and Solutions
2.12.4 Samyang Biopharmaceuticals Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.12.5 Samyang Biopharmaceuticals Recent Developments and Future Plans
2.13 Johnson & Johnson
2.13.1 Johnson & Johnson Details
2.13.2 Johnson & Johnson Major Business
2.13.3 Johnson & Johnson Novel Drug Delivery Systems Product and Solutions
2.13.4 Johnson & Johnson Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.13.5 Johnson & Johnson Recent Developments and Future Plans
2.14 TOLMAR
2.14.1 TOLMAR Details
2.14.2 TOLMAR Major Business
2.14.3 TOLMAR Novel Drug Delivery Systems Product and Solutions
2.14.4 TOLMAR Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.14.5 TOLMAR Recent Developments and Future Plans
2.15 Astellas
2.15.1 Astellas Details
2.15.2 Astellas Major Business
2.15.3 Astellas Novel Drug Delivery Systems Product and Solutions
2.15.4 Astellas Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.15.5 Astellas Recent Developments and Future Plans
2.16 AMAG Pharmaceuticals
2.16.1 AMAG Pharmaceuticals Details
2.16.2 AMAG Pharmaceuticals Major Business
2.16.3 AMAG Pharmaceuticals Novel Drug Delivery Systems Product and Solutions
2.16.4 AMAG Pharmaceuticals Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.16.5 AMAG Pharmaceuticals Recent Developments and Future Plans
2.17 AbbVie
2.17.1 AbbVie Details
2.17.2 AbbVie Major Business
2.17.3 AbbVie Novel Drug Delivery Systems Product and Solutions
2.17.4 AbbVie Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.17.5 AbbVie Recent Developments and Future Plans
2.18 Dr Reddy
2.18.1 Dr Reddy Details
2.18.2 Dr Reddy Major Business
2.18.3 Dr Reddy Novel Drug Delivery Systems Product and Solutions
2.18.4 Dr Reddy Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.18.5 Dr Reddy Recent Developments and Future Plans
2.19 AstraZeneca
2.19.1 AstraZeneca Details
2.19.2 AstraZeneca Major Business
2.19.3 AstraZeneca Novel Drug Delivery Systems Product and Solutions
2.19.4 AstraZeneca Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.19.5 AstraZeneca Recent Developments and Future Plans
2.20 Aspen
2.20.1 Aspen Details
2.20.2 Aspen Major Business
2.20.3 Aspen Novel Drug Delivery Systems Product and Solutions
2.20.4 Aspen Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.20.5 Aspen Recent Developments and Future Plans
2.21 Acrotech Biopharma
2.21.1 Acrotech Biopharma Details
2.21.2 Acrotech Biopharma Major Business
2.21.3 Acrotech Biopharma Novel Drug Delivery Systems Product and Solutions
2.21.4 Acrotech Biopharma Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.21.5 Acrotech Biopharma Recent Developments and Future Plans
2.22 TWi Pharmaceuticals
2.22.1 TWi Pharmaceuticals Details
2.22.2 TWi Pharmaceuticals Major Business
2.22.3 TWi Pharmaceuticals Novel Drug Delivery Systems Product and Solutions
2.22.4 TWi Pharmaceuticals Novel Drug Delivery Systems Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.22.5 TWi Pharmaceuticals Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Novel Drug Delivery Systems Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Novel Drug Delivery Systems by Company Revenue
3.2.2 Top 3 Novel Drug Delivery Systems Players 麻豆原创 Share in 2023
3.2.3 Top 6 Novel Drug Delivery Systems Players 麻豆原创 Share in 2023
3.3 Novel Drug Delivery Systems 麻豆原创: Overall Company Footprint Analysis
3.3.1 Novel Drug Delivery Systems 麻豆原创: Region Footprint
3.3.2 Novel Drug Delivery Systems 麻豆原创: Company Product Type Footprint
3.3.3 Novel Drug Delivery Systems 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Novel Drug Delivery Systems Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Novel Drug Delivery Systems 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Novel Drug Delivery Systems Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Novel Drug Delivery Systems 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Novel Drug Delivery Systems Consumption Value by Type (2019-2030)
6.2 North America Novel Drug Delivery Systems 麻豆原创 Size by Application (2019-2030)
6.3 North America Novel Drug Delivery Systems 麻豆原创 Size by Country
6.3.1 North America Novel Drug Delivery Systems Consumption Value by Country (2019-2030)
6.3.2 United States Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Novel Drug Delivery Systems Consumption Value by Type (2019-2030)
7.2 Europe Novel Drug Delivery Systems Consumption Value by Application (2019-2030)
7.3 Europe Novel Drug Delivery Systems 麻豆原创 Size by Country
7.3.1 Europe Novel Drug Delivery Systems Consumption Value by Country (2019-2030)
7.3.2 Germany Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Novel Drug Delivery Systems Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Novel Drug Delivery Systems Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Novel Drug Delivery Systems 麻豆原创 Size by Region
8.3.1 Asia-Pacific Novel Drug Delivery Systems Consumption Value by Region (2019-2030)
8.3.2 China Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Novel Drug Delivery Systems Consumption Value by Type (2019-2030)
9.2 South America Novel Drug Delivery Systems Consumption Value by Application (2019-2030)
9.3 South America Novel Drug Delivery Systems 麻豆原创 Size by Country
9.3.1 South America Novel Drug Delivery Systems Consumption Value by Country (2019-2030)
9.3.2 Brazil Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Novel Drug Delivery Systems Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Novel Drug Delivery Systems Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Novel Drug Delivery Systems 麻豆原创 Size by Country
10.3.1 Middle East & Africa Novel Drug Delivery Systems Consumption Value by Country (2019-2030)
10.3.2 Turkey Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Novel Drug Delivery Systems 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Novel Drug Delivery Systems 麻豆原创 Drivers
11.2 Novel Drug Delivery Systems 麻豆原创 Restraints
11.3 Novel Drug Delivery Systems Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Novel Drug Delivery Systems Industry Chain
12.2 Novel Drug Delivery Systems Upstream Analysis
12.3 Novel Drug Delivery Systems Midstream Analysis
12.4 Novel Drug Delivery Systems Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Amgen
Teva
Roche
UCB (Union Chimique Belge)
Celgene
Merck
Gilead Sciences
Sanofi
Pfizer
Takeda
Bausch&Lomb
Samyang Biopharmaceuticals
Johnson & Johnson
TOLMAR
Astellas
AMAG Pharmaceuticals
AbbVie
Dr Reddy
AstraZeneca
Aspen
Acrotech Biopharma
TWi Pharmaceuticals
听
听
*If Applicable.
